These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33599738)

  • 1. Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis.
    Hanrahan C; Lee T
    Am J Health Syst Pharm; 2021 Mar; 78(8):697-704. PubMed ID: 33599738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of infliximab and its biosimilars in patients with rheumatoid arthritis presenting an insufficient response to methotrexate : A network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2023 Mar; 82(2):114-122. PubMed ID: 34228181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Int J Rheum Dis; 2018 May; 21(5):922-929. PubMed ID: 29671942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
    Ascef BO; Almeida MO; Medeiros-Ribeiro AC; Oliveira de Andrade DC; Oliveira Junior HA; de Soárez PC
    JAMA Netw Open; 2023 May; 6(5):e2315872. PubMed ID: 37234004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison.
    Baji P; Péntek M; Czirják L; Szekanecz Z; Nagy G; Gulácsi L; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S53-64. PubMed ID: 24832836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2023 Feb; 82(1):64-70. PubMed ID: 33999266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis.
    Ascef BO; Almeida MO; de Medeiros Ribeiro AC; Andrade DCO; de Oliveira Júnior HA; Pereira TV; de Soárez PC
    Syst Rev; 2021 Jul; 10(1):205. PubMed ID: 34274019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.
    Tanaka E; Kawahito Y; Kohno M; Hirata S; Kishimoto M; Kaneko Y; Tamai H; Seto Y; Morinobu A; Sugihara T; Murashima A; Kojima M; Mori M; Ito H; Kojima T; Sobue Y; Nishida K; Matsushita I; Nakayama T; Yamanaka H; Harigai M
    Mod Rheumatol; 2022 Jan; 32(1):74-86. PubMed ID: 33706664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of etanercept biosimilars in comparison with etanercept in patients with rheumatoid arthritis who have insufficient response to methotrexate: A network meta-analysis.
    Lee YH; Song GG
    Int J Clin Pharmacol Ther; 2021 Dec; 59(12):760-767. PubMed ID: 34622769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
    Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
    Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study.
    Lila AM; Mazurov VI; Denisov LN; Nesmeyanova OB; Ilivanova EP; Eremeeva AV; Usacheva JV; Dokukina EA; Chernyaeva EV; Ivanov RA
    Rheumatol Int; 2019 Sep; 39(9):1537-1546. PubMed ID: 31292709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
    Bae SC; Lee YH
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):188-196. PubMed ID: 30574867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL
    Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis.
    Genovese MC; Sanchez-Burson J; Oh M; Balazs E; Neal J; Everding A; Hala T; Wojciechowski R; Fanjiang G; Cohen S
    Arthritis Res Ther; 2020 Mar; 22(1):60. PubMed ID: 32216829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.
    Kameda H; Uechi E; Atsumi T; Abud-Mendoza C; Kamei K; Matsumoto T; Ponce de Leon D; Rehman MI; Zhang M; Radominski SC
    Int J Rheum Dis; 2020 Jul; 23(7):876-881. PubMed ID: 32476277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis.
    de Oliveira Ascef B; Almeida MO; de Medeiros-Ribeiro AC; de Oliveira Andrade DC; de Oliveira Junior HA; de Soárez PC
    Sci Rep; 2023 Aug; 13(1):13699. PubMed ID: 37607959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
    Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A
    J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.